Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.77 |
| ▸ | NT5E | P21589 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.76 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.67 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.67 |
| ▸ | CA5A | P35218 | 1/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.60 |
| ▸ | AHCY | P23526 | 2/20 | 0.60 |
| ▸ | NADK | O95544 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2404114 | 1.00 | ADORA3 (0.77) | ADORA3NT5ELMNAHIF1ADNMT1 | |
| SCHEMBL19849513 | 1.00 | ADORA3 (0.77) | ADORA3NT5ELMNAHIF1ADNMT1 | |
| SCHEMBL2047953 | 0.92 | ADORA3 (0.66) | ADORA3NT5ELMNAHIF1ADNMT1 | |
| SCHEMBL5347893 | 0.89 | ADORA3 (0.78) | ADORA3NT5ELMNAHIF1ADNMT1 | |
| SCHEMBL5347901 | 0.89 | ADORA3 (0.78) | ADORA3NT5ELMNAHIF1ADNMT1 | |
| SCHEMBL2118563 | 0.88 | ADORA3 (0.78) | ADORA3NT5ELMNAHIF1ADNMT1 | |
| SCHEMBL2118571 | 0.88 | ADORA3 (0.78) | ADORA3NT5ELMNAHIF1ADNMT1 | |
| SCHEMBL15926825 | 0.88 | ADORA3 (0.78) | ADORA3NT5ELMNAHIF1ADNMT1 | |
| SCHEMBL17752649 | 0.88 | NT5E (0.81) | ADORA3NT5ELMNAHIF1ADNMT1 | |
| SCHEMBL19843952 | 0.88 | NT5E (0.81) | ADORA3NT5ELMNAHIF1ADNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189706-B2 | C2,5′-disubstituted and N6,C2,5′-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | UNIVERSITEIT LEIDEN (NL) | 2007-03-13 | — | — | US | claimed |
| US-20040127452-A1 | C2,5'-disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | UNIVERSITEIT LEIDEN (NL) | 2004-07-01 | — | — | US | claimed |
| US-7189706-B2 | C2,5′-disubstituted and N6,C2,5′-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | UNIVERSITEIT LEIDEN (NL) | 2007-03-13 | — | — | US | disclosed |
| US-20040127452-A1 | C2,5'-disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | UNIVERSITEIT LEIDEN (NL) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127452-A1 | C2,5'-disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885NT5E 27/4885LMNA 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.